Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02494999 | A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants | PHASE3 | COMPLETED | 1,200 | — | — | Jun 1, 2016 | Oct 1, 2019 | May 13, 2020 | 4 | China |
| Arm | Type | Description |
|---|---|---|
| 13-valent pneumococcal conjugate vaccine | EXPERIMENTAL | Single 0.5 ml dose will be given via intramuscular injection in Month 0,2,4 and 10 |
| Prevnar 13 | ACTIVE_COMPARATOR | Single 0.5 ml dose will be given via intramuscular injection in Month 0,2,4 and 10 |
| Name | Type | Description |
|---|---|---|
| 13-valent pneumococcal conjugate vaccine | BIOLOGICAL | 0.5ml vaccine produced by Beijing Minhai Biotechnology Co., Ltd.,three doses with 2 month interval, a booster dose 10 months after the first dose |
| Prevnar 13 | BIOLOGICAL | 0.5ml vaccine produced by Wyeth,three doses with 2 month interval, a booster dose 10 months after the first dose |
Inclusion Criteria: * Aged 42-77 days old on the day of inclusion * Subjects' legal guardians are able to understand and sign the informed consent * Subjects' legal guardians can and will comply with the requirements of the protocol * Subjects with temperature \<=37.0°C on axillary setting Exclusi...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE3 | Tozorakimab |
| GSK plc Sponsored ADR | GSK | 3 | PHASE1 | Pn-MAPS30plus, PCV20 |
| Pfizer Inc. | PFE | 4 | — | Receipt of PCV20 |
| Sanofi SA Sponsored ADR | SNY | 1 | — | Undisclosed |
| Gilead Sciences, Inc. | GILD | 1 | — | Undisclosed |
| Grace Therapeutics, Inc. | GRCE | 1 | NA | Undisclosed |
| Co-Diagnostics, Inc. | CODX | 1 | — | Undisclosed |